Advertisement

Japanese Journal of Radiology

, Volume 37, Issue 6, pp 494–499 | Cite as

Radiation with concomitant superselective intra-arterial cisplatin infusion for maxillary sinus squamous cell carcinoma

  • Takeshi EbaraEmail author
  • Ken Ando
  • Jun Eishima
  • Masami Suzuki
  • Takeshi Kawakami
  • Hiroyuki Horikoshi
  • Yoshio Tamaki
Original Article
  • 88 Downloads

Abstract

Purpose

To assess the efficacy and prognostic factors after superselective intra-arterial chemoradiation (RADPLAT) for maxillary sinus squamous cell carcinoma (MS-SCC).

Materials and methods

Prognostic significance of age, gender, T and N factors, gross tumor volume of the primary-site (GTV), total cisplatin dosage, and total cisplatin dosage per GTV (CDDP/GTV) for primary-site recurrence-free survival rate (PRFS) were analyzed. RADPLAT was administered to 27 patients. The median follow-up period was 42.1 months.

Results

The 3-year rates of overall survival and PRFS were 59.2% and 53.9%, respectively. In univariate analysis, age, male, and total cisplatin dosage were significant factors for PRFS. In multivariate analysis, lymph node metastasis was significant factors for PRFS, and gender and total cisplatin dosage weakly influenced PRFS. In acute phase, no patient showed ≥ grade 3 hematologic toxicity, and grade 3 mucositis developed in 5 patients. Late toxicities were recognized in 3 patients (grade 2 phlegmon of the face, grade 3 maxillofacial osteonecrosis, and retinopathy). Twelve patients (44%) experienced recurrences. Of them, 8 patients showed recurrence at the primarysite.

Conclusion

RADPLAT was effective for MS-SCC, with acceptable toxicity. Total cisplatin dosage is suggested to be important for primary tumor control.

Keywords

RADPLAT Maxillary sinus squamous cell carcinoma Radiotherapy Cisplatin per tumor volume Prognostic factor 

Notes

Funding

This research was supported by Grand-in-Aid (B-10, 2017) of Gunma Prefectural Cancer Center in Japan.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in the present study were in accordance with the ethical standards of the institutional committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

References

  1. 1.
    Committee JSfhaNCCR. Report of Head and Neck Cancer Registry of Japan Clinical Statistics of Registered Patients, 2015.Google Scholar
  2. 2.
    Ogawa K, Toita T, Kakinohana Y, et al. Postoperative radiotherapy for squamous cell carcinoma of the maxillary sinus: analysis of local control and late complications. Oncol Rep. 2001;8:315–9.Google Scholar
  3. 3.
    Bristol IJ, Ahamad A, Garden AS, et al. Postoperative radiotherapy for maxillary sinus cancer: long-term outcomes and toxicities of treatment. Int J Radiat Oncol Biol Phys. 2007;68:719–30.CrossRefGoogle Scholar
  4. 4.
    Hayashi T, Nonaka S, Bandoh N, Kobayashi Y, Imada M, Harabuchi Y. Treatment outcome of maxillary sinus squamous cell carcinoma. Cancer. 2001;92:1495–503.CrossRefGoogle Scholar
  5. 5.
    Yoshimura R, Shibuya H, Ogura I, et al. Trimodal combination therapy for maxillary sinus carcinoma. Int J Radiat Oncol Biol Phys. 2002;53:656–63.CrossRefGoogle Scholar
  6. 6.
    Shiga K, Yokoyama J, Hashimoto S, et al. Combined therapy after superselective arterial cisplatin infusion to treat maxillary squamous cell carcinoma. Otolaryngol Head Neck Surg. 2007;136:1003–9.CrossRefGoogle Scholar
  7. 7.
    Homma A, Oridate N, Suzuki F, et al. Superselective high-dose cisplatin infusion with concomitant radiotherapy in patients with advanced cancer of the nasal cavity and paranasal sinuses: a single institution experience. Cancer. 2009;115:4705–14.CrossRefGoogle Scholar
  8. 8.
    Homma A, Sakashita T, Yoshida D, et al. Superselective intra-arterial cisplatin infusion and concomitant radiotherapy for maxillary sinus cancer. Br J Cancer. 2013;109:2980–6.CrossRefGoogle Scholar
  9. 9.
    Robbins KT, Kumar P, Harris J, et al. Supradose intra-arterial cisplatin and concurrent radiation therapy for the treatment of stage IV head and neck squamous cell carcinoma is feasible and efficacious in a multi-institutional setting: results of Radiation Therapy Oncology Group Trial 9615. J Clin Oncol. 2005;23:1447–544.CrossRefGoogle Scholar
  10. 10.
    Ethics guideline for medical research concerning humans. Ministry of education, culture, sports, science and technology, Japan. December 22, 2014.Google Scholar
  11. 11.
    Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, Version 3.0, DCTD, NCI, NIH, DHHS. March 31, 2003.Google Scholar
  12. 12.
    Kanda Y. Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transpl. 2013;48:452–8.CrossRefGoogle Scholar
  13. 13.
    Homma A, Onimaru R, Matsuura K, et al. Dose-finding and efficacy confirmation trial of the superselective intra-arterial infusion of cisplatin and concomitant radiotherapy for locally advanced maxillary sinus cancer (Japan Clinical Oncology Group 1212): Dose-finding phase. Head Neck. 2018;40:475–84.CrossRefGoogle Scholar
  14. 14.
    Robbins KT, Hoffman RM. "Decadose" effects of cisplatin on squamous cell carcinoma of the upper aerodigestive tract I. Histoculture experiments. Laryngoscope. 1996;106:32–6.CrossRefGoogle Scholar
  15. 15.
    Robbins KT, Storniolo AM, Hryniuk WM, Howell SB. "Decadose" effects of cisplatin on squamous cell carcinoma of the upper aerodigestive tract II. Clinical studies. Laryngoscope. 1996;106:37–42.CrossRefGoogle Scholar
  16. 16.
    Rasch CR, Hauptmann M, Schornagel J, et al. Intra-arterial versus intravenous chemoradiation for advanced head and neck cancer: results of a randomized phase 3 trial. Cancer. 2010;116:2159–65.CrossRefGoogle Scholar
  17. 17.
    Al-Mamgani A, Monserez D, Rooij P, Verduijn GM, Hardillo JA, Levendag PC. Highly-conformal intensity-modulated radiotherapy reduced toxicity without jeopardizing outcome in patients with paranasal sinus cancer treated by surgery and radiotherapy or (chemo)radiation. Oral Oncol. 2012;48:905–11.CrossRefGoogle Scholar
  18. 18.
    Suh YG, Lee CG, Kim H, et al. Treatment outcomes of intensity-modulated radiotherapy versus 3D conformal radiotherapy for patients with maxillary sinus cancer in the postoperative setting. Head Neck. 2016;38(Suppl 1):E207–E213213.CrossRefGoogle Scholar
  19. 19.
    Paulino A, Fisher S, Marks J. Is prophylactic neck irradiation indicated in patients with squamous cell carcinoma of the maxillary sinus? Int J Radiat Oncol Biol Phys. 1997;39:283–9.CrossRefGoogle Scholar
  20. 20.
    Le QT, Fu KK, Kaplan MJ, Terris DJ, Fee WE, Goffinet DR. Lymph node metastasis in maxillary sinus carcinoma. Int J Radiat Oncol Biol Phys. 2000;46:541–9.CrossRefGoogle Scholar

Copyright information

© Japan Radiological Society 2019

Authors and Affiliations

  1. 1.Department of Radiation OncologyGunma Prefectural Cancer CenterOtaJapan
  2. 2.Department of Head and Neck SurgeryGunma Prefectural Cancer CenterOtaJapan
  3. 3.Department of RadiologyGunma Prefectural Cancer CenterOtaJapan
  4. 4.Department of Radiation OncologyTsukuba University HospitalTsukubaJapan

Personalised recommendations